Loading...
Please wait, while we are loading the content...
Similar Documents
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
| Content Provider | Scilit |
|---|---|
| Author | Gallipoli, Paolo Cook, Amy Rhodes, Susan Hopcroft, Lisa Wheadon, Helen Whetton, Anthony D. Jørgensen, Heather G. Bhatia, Ravi Holyoake, Tessa L. |
| Copyright Year | 2014 |
| Description | Key Points The JAK2/STAT5 pathway is a relevant therapeutic target in CML SPCs. Targeting the JAK2/STAT5 pathway by nilotinib and RUX in combination leads to enhanced eradication of primitive CML stem cells. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148771/pdf |
| Ending Page | 1501 |
| Page Count | 10 |
| Starting Page | 1492 |
| DOI | 10.1182/blood-2013-12-545640 |
| Journal | Blood |
| Issue Number | 9 |
| Volume Number | 124 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2014-08-28 |
| Access Restriction | Open |
| Subject Keyword | Research and Experimental Medicine Nilotinib Key Points Cml Stem Jak2/stat5 Pathway Primitive Cml Relevant Therapeutic Vivo Key Ruxolitinib Contributes Enhanced Eradication Journal: Blood (Vol- 110, Issue- 9) |
| Content Type | Text |
| Resource Type | Article |